ReviewGene expression2014
Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma.
Review in Gene expression, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Fish and Food-Fatale: Food-borne TrematodeHelminthologia · 2023Review
- Downregulation of miR-145 alleviates ox-LDL-induced inflammation by targeting QKI in macrophages.American journal of translational research · 2022Article
- OCaMIR-A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum.Frontiers in oncology · 2021Review
- LncRNA PCAT6 increased cholangiocarcinoma cell proliferation and invasion via modulating miR-330-5p.American journal of translational research · 2019Article
- Reduced atherosclerosis lesion size, inflammatory response in miR-150 knockout mice via macrophage effects.Journal of lipid research · 2018Article
- Extracellular vesicle-encapsulated miR-30e suppresses cholangiocarcinoma cell invasion and migration via inhibiting epithelial-mesenchymal transition.Oncotarget · 2018Article
- Inhibition of miR-10a-5p suppresses cholangiocarcinoma cell growth through downregulation of Akt pathway.OncoTargets and therapy · 2018Article
- MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7.Oncology letters · 2018Article
- Recent Advances in Understanding Cholangiocarcinoma.F1000Research · 2017Review
- Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma.Epigenetics · 2016Article
- A functional microRNA library screen reveals miR-410 as a novel anti-apoptotic regulator of cholangiocarcinoma.BMC cancer · 2016Article
- Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers.International journal of molecular sciences · 2016Review
- The role of miRNAs in cholangiocarcinoma.Hepatic oncology · 2016Review
- MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment.Journal of clinical medicine · 2015Review
- MicroRNAs and benign biliary tract diseases.Seminars in liver disease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The microRNAs (miRNAs) are small noncoding RNAs that are potent regulators of gene expression and can regulate several diverse biological functions. This minireview provides an overview of recent studies that have examined the role and involvement of miRNAs in cholangiocarcinomas. These studies provide evidence for deregulated expression of miRNA and are providing new insights into the potential contribution of these in the pathogenesis of cholangiocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.